Dynamic Healthcare M&A Database

Acquiring Party	Boston Scientific Corporation (NYSE: BSX), a major medical device manufacturer focused on cardiovascular and other interventional specialties.
Transferring Party	Technology for treating symptomatic benign prostatic hyperplasia (BPH) from Celsion Corporation (Amex: CLN), a developer of oncology drugs.
Sector	Medical Devices
Date	June 21, 2007
Analysis Since 2004, BSX has exclusively distributed the Prolieve(R)Thermodilatation System, a non-surgical, less invasive, microwave-based treatment for symptomatic BPH which is routinely performed in the physician's office. The system's transurethral catheter uses microwave heating to reduce the enlarged prostate tissue and improve urine flow. BSX had an option to buy the technology for $60m.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 2Q07